Anaemia in cancer patients: pathophysiology, incidence and treatment

This review focuses on the pathophysiology, incidence and treatment of anaemia in cancer patients. Causative factors such as different chemotherapy regimens and patient risk factors for the development of anaemia are discussed in order to identify the patient group that is most likely to receive red...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical investigation 2005-12, Vol.35 (s3), p.26-31
Main Authors: Bokemeyer, C., Oechsle, K., Hartmann, J.-T.
Format: Article
Language:English
Subjects:
Anaemia
Anemia - complications
Anemia - physiopathology
Anemia - therapy
Antineoplastic Agents - adverse effects
cancer
Darbepoetin alfa
Drug Administration Schedule
erythropoetin
Erythropoiesis - drug effects
Erythropoietin - administration & dosage
Erythropoietin - analogs & derivatives
Erythropoietin - therapeutic use
haemoglobin values
Hematinics - administration & dosage
Hematinics - therapeutic use
Humans
Neoplasms - complications
Neoplasms - physiopathology
prognosis
Recombinant Proteins
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review focuses on the pathophysiology, incidence and treatment of anaemia in cancer patients. Causative factors such as different chemotherapy regimens and patient risk factors for the development of anaemia are discussed in order to identify the patient group that is most likely to receive red blood cell transfusions and would thus have the largest benefit from treatment with erythropoietic proteins. The data available with recombinant human erythropoietin alfa, recombinant human erythropoietin beta and darbepoetin alfa are described in more detail and the significant benefit of treating cancer anaemia by these molecules is outlined. Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients’ situation.
ISSN:0014-2972
1365-2362
DOI:10.1111/j.1365-2362.2005.01527.x